Composition of the substance
active substance: 1 ml of solution contains 50mg latanoprost;
excipients: sodium chloride, sodium dihydrogen phosphate monohydrate, sodium hydrofosfate anhydrous, benzalkonium chloride, hydrochloric acid concentrated, sodium hydroxide, water for injection.
Eye drops.
Indication
Reduced intraocular pressure (IOP) in patients with open-angle glaucoma and increased intraocular pressure.
Reduced increased intraocular pressure in children with increased intraocular pressure and childhood glaucoma.
Pharmacological properties
Pharmacodynamics.
The active substance of latanoprost is an analogue of prostaglandin F2α, a selective agonist of the простаноидного receptor FP, which reduces intraocular pressure, increasing the outflow of aqueous humor of the eye. The reduction of intraocular pressure in humans begins approximately three to four hours after the administration of the drug, and the maximum effect is achieved in eight to twelve hours. Pressure reduction is maintained for at least 24 hours.
Pharmacokinetics.
Latanoprost (molecular weight 432.58) is a precursor of the drug in the form of isopropyl ether, which in itself is inactive, but becomes biologically active after hydrolysis to the latanoprost acid.
The predecessor of the drug is well absorbed through the cornea, and the entire drug that gets into the watery eye moisture is hydrolysed during the passage through the cornea.
Studies indicate that the maximum concentration of the drug in watery humans is reached approximately 2 hours after local administration. Acid latanoprost is practically not metabolised in the eyes. The main metabolism occurs in the liver. The half-life of blood plasma in humans is 17 minutes.
Producer
«UNIMED PHARMA Ltd».
Location of the manufacturer and the address of the place of its operation
Orieskova 11, 821 05 Bratislava, Slovak Republic.